Last reviewed · How we verify
NCT04220476: CIMER
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Phase 2 trial testing Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) in Breast Cancer. Withdrawn.
31 December 2025
Quick facts
| Lead sponsor | Weill Medical College of Cornell University |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 4 March 2020 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2028 |
Drugs / interventions tested
- Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
- Letrozole 2.5Mg Tab — full drug profile →
- Palbociclib 125mg (palbociclib-125mg) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Weill Medical College of Cornell University
Who can join
Adults 18 to 90, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization.
Yang Y, Luo J, Chen X, Yang Z, et al · · 2020 · cited 53× · PMID 32933570 · DOI 10.1186/s13046-020-01693-w -
Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians.
Marazzi F, Orlandi A, Manfrida S, Masiello V, et al · · 2020 · cited 28× · PMID 32846945 · DOI 10.3390/cancers12092390
Verify or expand the search:
- PubMed search for NCT04220476
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Trials testing the same drug.
- NCT04563507 — Combined Immunotherapies in Metastatic ER+ Breast Cancer · Phase 2 · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Weill Medical College of Cornell University trials
Trials by the same sponsor.
- NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
- NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
- NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04220476 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
- Last refreshed: 21 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220476.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing